Skip To Main Content
Určeno pro odbornou veřejnost
Campus
Campus
View Full Results

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
ASMD Phenotypes

ASMD Phenotypes

Číst více
ASMD Phenotypes

ASMD Phenotypes

Číst více
ASMD Phenotypes

ASMD Phenotypes

Číst více
Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Číst více
Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Číst více
Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Číst více
Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Číst více
Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Číst více
Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control

Číst více
Real-world evidence of treatment intensification in people with T2D inadequately controlled on GLP-1 RAs

Real-world evidence of treatment intensification in people with T2D inadequately controlled on GLP-1 RAs

Číst více
Real-world evidence of treatment intensification in people with T2D inadequately controlled on GLP-1 RAs

Real-world evidence of treatment intensification in people with T2D inadequately controlled on GLP-1 RAs

Číst více
Real-world evidence of treatment intensification in people with T2D inadequately controlled on GLP-1 RAs

Real-world evidence of treatment intensification in people with T2D inadequately controlled on GLP-1 RAs

Číst více